Literature DB >> 7712595

Eicosanoids and the immunology of cancer.

M R Young1.   

Abstract

Studies in both cancer patients and in animal tumor models have shown that immune defenses can mediate destruction of tumor, but these defenses are often functioning at a suppressed or suboptimal level. Frequently, prostaglandins, mainly PGE2, have been implicated in this tumor-associated subversion of immune function, with immune reactivities to tumor typically being enhanced by prostaglandin synthesis inhibitor. Both the tumor and tumor-induced host immune suppressive macrophages have the capacity to suppress immune functions through their production of PGE2. Although the inhibitory functions have been more widely studied, recent evaluations of the effects of PGE2 have led to the surprising realization that not all of the PGE2's effects are inhibitory to immune function. Summarized below are some of the well characterized inhibitory effects of PGE2, as well as the lesser studied stimulatory effects of PGE2 toward the effector cells that are considered to be important in the immune defense against cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7712595     DOI: 10.1007/bf00666103

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  86 in total

Review 1.  T-cell subsets and cytokines in parasitic infections.

Authors:  F E Cox; F Y Liew
Journal:  Immunol Today       Date:  1992-11

Review 2.  Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis.

Authors:  I J Fidler
Journal:  Res Immunol       Date:  1992-02

3.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

Authors:  M K Gately; B B Desai; A G Wolitzky; P M Quinn; C M Dwyer; F J Podlaski; P C Familletti; F Sinigaglia; R Chizonnite; U Gubler
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

4.  Protein phosphatases limit tumor motility.

Authors:  M R Young; Y Lozano; A Djorjevic; G D Maier
Journal:  Int J Cancer       Date:  1993-07-30       Impact factor: 7.396

5.  Altered eicosanoid levels in human colon cancer.

Authors:  B Rigas; I S Goldman; L Levine
Journal:  J Lab Clin Med       Date:  1993-11

6.  The LMI test in colon, breast and lung cancer long survivors.

Authors:  M Fazio; F Calabrese; C Coluccia; S Giacomasso; C Casadio; M Mancuso; L Negri; V Mastromatteo
Journal:  Panminerva Med       Date:  1992 Apr-Jun       Impact factor: 5.197

7.  Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer.

Authors:  M C Fariñas; V Rodriguez-Valverde; M T Zarrabeitia; J A Parra-Blanco; J Sanz-Ortiz
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

8.  Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

Authors:  R M Bukowski; W Sharfman; S Murthy; P Rayman; R Tubbs; J Alexander; G T Budd; J S Sergi; L Bauer; V Gibson
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2.

Authors:  M R Young; M E Young; K Kim
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

10.  Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma.

Authors:  M R Young; C S Hoover
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

View more
  14 in total

1.  Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.

Authors:  O Gallo; A Franchi; L Magnelli; I Sardi; A Vannacci; V Boddi; V Chiarugi; E Masini
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

2.  Diminution of the development of experimental metastases produced by murine metastatic lines in essential fatty acid-deficient host mice.

Authors:  A Mannini; L Calorini; G Mugnai; S Ruggieri
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

3.  Enhancement of nitric oxide release in mouse inflammatory macrophages co-cultivated with tumor cells of a different origin.

Authors:  Lido Calorini; Francesca Bianchini; Antonella Mannini; Gabriele Mugnai; Salvatore Ruggieri
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Polyamines reverse non-steroidal anti-inflammatory drug-induced toxicity in human colorectal cancer cells.

Authors:  Alun Hughes; Nicholas I Smith; Heather M Wallace
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

5.  In vivo indomethacin treatment causes microglial activation in adult mice.

Authors:  M M Prechel; C Ding; R L Washington; M S Kolodziej; M R Young
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

6.  Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.

Authors:  M R Young; J Ihm; Y Lozano; M A Wright; M M Prechel
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

7.  Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma.

Authors:  Oreste Gallo; Nicola Schiavone; Laura Papucci; Iacopo Sardi; Lucia Magnelli; Alessandro Franchi; Emanuela Masini; Sergio Capaccioli
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 8.  Associations between physical activity and susceptibility to cancer: possible mechanisms.

Authors:  R J Shephard; P N Shek
Journal:  Sports Med       Date:  1998-11       Impact factor: 11.136

9.  Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells.

Authors:  J Ghosh; C E Myers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Premalignant lesions skew spleen cell responses to immune modulation by adipocytes.

Authors:  Silvana A Vielma; Richard L Klein; Corinne A Levingston; M Rita I Young
Journal:  Anticancer Res       Date:  2013-05       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.